APRICUS BIOSCIENCES TO PRESENT AT THE FSX INVESTOR CONFERENCE IN PHOENIX, AZ ON OCTOBER 29, 2010
-
SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences ("Apricus Bio") (Nasdaq: APRI) today announced that Bassam Damaj, Ph.D., President and Chief Executive Officer, will present at the FSX (Financial Services Exchange, Inc.) investors conference being held at the Ritz Carlton in Phoenix, AZ from October 28-30, 2010. Dr. Damaj's presentation is scheduled for Friday morning, October 29, 2010. The event is not being webcast.
FSX is the premier investment conference organization in the United States, hosting quarterly investment conferences around the country, providing opportunities for networking and one-on-one communication between independent broker/dealers and companies seeking exposure or funding. FSX conferences also provide a forum for direct investment programs, mutual funds, and asset management companies. For more information visit: www.fsxone.com.
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com.
Contacts:
Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations & Corporate Development Apricus Bio, Inc.
(858) 848-4249
[email protected]
Apricus Bio Investor Relations
Paula Schwartz
Apricus Bio, Inc. Rx Communications Group, LLC
(917) 322-2216
[email protected]